Sources | Names Used |
---|---|
CTRPv2 | erlotinib:PLX-4032 (2:1 mol/mol) |
PharmacoGx | erlotinib:PLX-4032 (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CDH19 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-06 |
mRNA | SOX15 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-06 |
mRNA | LYPD3 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-06 |
mRNA | MIA | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-06 |
mRNA | SVIL | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
mRNA | CLDN4 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-06 |
mRNA | TFAP2C | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-06 |
mRNA | AIM1L | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-06 |
mRNA | GAS7 | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-06 |
mRNA | PPP1R14C | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-06 |